Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience

Haemophilia - Tập 15 Số 2 - Trang 487-493 - 2009
Abdol Majid Cheraghali1, Hassan Abolghasemi
1Iranian Blood Transfusion Organization Research Center, Tehran, Iran. [email protected]

Tóm tắt

Summary.  In 1974, the government of Iran established Iranian Blood Transfusion Organization (IBTO) as national and centralized transfusion system. Since then donations of blood may not be remunerated and therapy with blood and its components are free of charges for all Iranian patients. Donations are meticulously screened through interviewing donors and lab testing the donations using serological methods. Currently, Iranian donors donate 1 735 000 units of blood annually (donation index: 25/1000 population). Implementation of a highly efficient donor selection programme, including donors interview, establishment of confidential unit exclusion programme and laboratory screening of donated bloods by IBTO have led to seroprevalence rates of 0.41%, 0.12% and 0.004% for HBV, HCV and HIV in donated bloods respectively. Since 2004, IBTO has initiated a programme to enter into a contract fractionation agreement for the surplus of recovered plasma produced in its blood collecting centres. Although IBTO has used this project as a mean to improve national transfusion system through upgrading its quality assurance systems, IBTO fractionation project has played a major role in improving availability of plasma‐derived medicines in Iran. During 2006–2007, this project furnished the Iran market with 44% and 14% of its needs to the intravenous immunoglobulin and albumin, respectively. Iranian experience showed that contract fractionation of plasma in countries with organized centralized transfusion system, which lack national plasma fractionation facility, in addition to substantial saving on national health resource and enhancing availability of plasma‐derived medicines, could serve as a useful means to improve national blood safety profile.

Từ khóa


Tài liệu tham khảo

World Health Organization, 2008, Blood transfusion safety

10.7326/0003-4819-136-4-200202190-00011

10.1016/j.socscimed.2006.08.023

10.4103/0973-6247.39505

10.1016/j.transci.2007.03.013

United Nation Development Program, Human development report 2007–2008 Iran

Alavian SM, 2005, Hepatitis C virus in Iran: epidemiology of an emerging infection, Arch Iranian Med, 8, 84

Kasraian L, 2007, Prevalence of major transfusion‐transmissible viral infections in blood donors attending fars blood transfusion center, shiraz, southern Iran: 2002–05, Iran J Med Sci, 32, 114

10.1097/MPH.0b013e3180437e02

10.1002/jmv.20634

Zandieh T, 2005, Transfusion transmitted virus (TTV) infection in thalassemic patients, Iran J Public Health, 34, 24

10.1111/j.1365-3148.2007.00794.x

10.1111/j.1365-2516.2004.00911.x

Cheraghali AM, 2006, Iran pharmaceutical market, Iran J Pharma Res, 5, 1

World Health Organization, 2005, WHO recommendations for the production, control and regulation of human plasma for fractionation

10.1111/j.1423-0410.1981.tb00689.x

10.1016/S1473-0502(02)00104-0

Thông tin
Thông tin xuất bản

Haemophilia

Tập 15 Số 2

487-493

Thông tin tác giả